These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 28292081)

  • 1. Tolerability profile of bevacizumab in metastatic colorectal cancer: about a Medical Department experience.
    Khmamouche MR; Mahfoud T; Bazine A; Tanz R; Ichou M; Errihani H
    Pan Afr Med J; 2016; 25():118. PubMed ID: 28292081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
    Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
    Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
    Antonuzzo L; Giommoni E; Pastorelli D; Latiano T; Pavese I; Azzarello D; Aieta M; Pastina I; Di Fabio F; Bertolini A; Corsi DC; Mogavero S; Angelini V; Pazzagli M; Di Costanzo F
    World J Gastroenterol; 2015 Jun; 21(23):7281-8. PubMed ID: 26109816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse effects of bevacizumab in metastatic colorectal cancer : a case report and literature review.
    Willems E; Gerne L; George C; D'Hondt M
    Acta Gastroenterol Belg; 2019; 82(2):322-325. PubMed ID: 31314196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
    Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
    Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis.
    Cao D; Zheng Y; Xu H; Ge W; Xu X
    Sci Rep; 2019 Dec; 9(1):20326. PubMed ID: 31889159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
    Hurwitz H; Saini S
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S26-34. PubMed ID: 17145522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings.
    Giantonio BJ
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S15-8. PubMed ID: 17145520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.
    Roohullah A; Wong HL; Sjoquist KM; Gibbs P; Field K; Tran B; Shapiro J; Mckendrick J; Yip D; Nott L; Gebski V; Ng W; Chua W; Price T; Tebbutt N; Chantrill L
    World J Gastroenterol; 2015 May; 21(17):5352-8. PubMed ID: 25954110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry.
    Tomita Y; Karapetis CS; Ullah S; Townsend AR; Roder D; Beeke C; Roy AC; Padbury R; Price TJ
    Acta Oncol; 2016; 55(4):480-5. PubMed ID: 26878155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing patients with metastatic colorectal cancer on bevacizumab.
    Lemmens L; Claes V; Uzzell M
    Br J Nurs; 2008 Aug 14-Sep 10; 17(15):944-9. PubMed ID: 18983014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When a good call leads to a bad connection: colovesical fistula in colorectal cancer treated with bevacizumab.
    Chen J; Smalligan RD; Nadesan S
    Hosp Pract (1995); 2016 Aug; 44(3):120-2. PubMed ID: 27309405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer.
    Akun E; Okutur K; Seber S; Korkmaz T; Aydin K; Bozkurt M; Namal E; Hasbal B; Tecimer C; Demir G
    J BUON; 2012; 17(4):669-76. PubMed ID: 23335523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer.
    Vrdoljak E; Omrčen T; Boban M; Hrabar A
    Anticancer Drugs; 2011 Feb; 22(2):191-7. PubMed ID: 21057306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk and management of venous thromboembolisms in bevacizumab-treated metastatic colorectal cancer patients.
    Yu I; Chen L; Ruan JY; Chang JT; Cheung WY
    Support Care Cancer; 2016 Mar; 24(3):1199-208. PubMed ID: 26286113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab in elderly patients with metastatic colorectal cancer.
    Sclafani F; Cunningham D
    J Geriatr Oncol; 2014 Jan; 5(1):78-88. PubMed ID: 24484722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.
    Passardi A; Scarpi E; Tamberi S; Cavanna L; Tassinari D; Fontana A; Pini S; Bernardini I; Accettura C; Ulivi P; Frassineti GL; Amadori D
    PLoS One; 2015; 10(8):e0134732. PubMed ID: 26244985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study.
    Hammerman A; Greenberg-Dotan S; Battat E; Feldhamer I; Bitterman H; Brenner B
    Acta Oncol; 2015 Feb; 54(2):164-70. PubMed ID: 25350524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.